Grifols A : Highlights from CMD 2022
>Long term financial targets delayed one year due to pipeline and Covid impacts - Grifols has confirmed during its CMD that it still maintains its long-term financial targets, but expects all figures to be reached one year later. At the time of the Biotest acquisition presentation, Grifols said it expects to reach sales of € 7bn and EBITDA of € 2.2bn (31% margin) by 2024e which compares with our EBITDA estimates of € 2.0bn in 2024 and € 2.3bn by 2025e. Likewise financ...Grifols is engaged in developing, manufacturing and distributing a range of plasma derivative products. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend the lives of individuals who suffer from chronic and acute conditions. Co. also specializes in providing infusion solutions, nutrition products, medical devices, diagnostic instrumentation and reagents for use in hospitals and clinics. Co.'s products and services are used by healthcare providers in approximately 100 countries. Co.'s business is organized into three divisions: Bioscience, Diagnostic, Hospital and Raw Materials.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.